Thermo Fisher Scientific Inc. $TMO Stock Holdings Lessened by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 126,252 shares of the medical research company’s stock after selling 2,012 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $61,289,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. CBIZ Investment Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the last quarter. Highline Wealth Partners LLC grew its position in Thermo Fisher Scientific by 126.9% in the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $30,000. Capital A Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after buying an additional 66 shares during the period. Finally, DiNuzzo Private Wealth Inc. grew its holdings in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after buying an additional 61 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TMO has been the subject of several recent analyst reports. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Leerink Partners increased their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $621.70.

Insider Buying and Selling

In other news, EVP Frederick M. Lowery sold 6,913 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $597.68, for a total value of $4,131,761.84. Following the completion of the sale, the executive vice president owned 14,367 shares in the company, valued at $8,586,868.56. This represents a 32.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michel Lagarde sold 32,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total value of $18,668,480.00. Following the transaction, the chief operating officer owned 65,480 shares in the company, valued at $38,200,377.20. This represents a 32.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 149,271 shares of company stock valued at $86,507,282. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.8%

Thermo Fisher Scientific stock opened at $606.16 on Friday. The firm has a market cap of $227.74 billion, a price-to-earnings ratio of 35.02, a price-to-earnings-growth ratio of 4.06 and a beta of 0.91. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $628.08. The firm’s 50 day moving average price is $580.33 and its two-hundred day moving average price is $515.03. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.